anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, food industry, pharmacy. SUBSTANCE: invention relates to medicinal compositions based on natural products and preparing curative preparations from vegetable raw, liquid high-molecular mineral, natural resins, vegetable oils, apiculture products. Proposed pharmaceutical curative composition includes dialcoholized extractive substances from propolis, snowdon rose, flower pollen, Leuzea carthamoides, Eleutherococcus senticosus, purified shilagit, pine galipot, elecampane, deadly night-shade, white lily and also nonextractive substances, among them, bee mother milk, flower pollen powder and cacao-containing substances taken in the definite ratio. Invention proposes also method of curative and curative-prophylactic use of the pharmaceutical composition where dose for adult, children and health humans is decreased as compared with that for curative dose by 3-5 times. Invention proposes also method of treatment of pharmaceutical curative composition that includes saturation of composition by nanoneuronic information in unit producing neuronic source of information field. This composition shows positive effect in patients with asthenic, stress states, increased fatiguability, in neurosis, vegetative-vascular dystonia, for prophylaxis of tumor development, allergic response reactions, cholesterol arteriosclerosis and as the preparation used in complex treatment of patients with chronic diseases and after therapeutic and surgery diseases. EFFECT: enhanced effectiveness of composition, improved method of treatment. 7 cl, 4 ex
OBJECTIVES: The association between immune-mediated thrombotic thrombocytopenic purpura (iTTP) and Sjögren disease (SjD) has been poorly investigated. This study presents the first retrospective cohort of iTTP-SjD aiming to identify risk factors for iTTP occurrence in SjD patients and examine their clinical course.
METHODS: Patients with iTTP-SjD were identified within the French TTP Registry based on American College of Rheumatology/European League Against Rheumatism 2016 criteria. A comparative analysis was conducted with two control groups comprising primary SjD (pSjD) patients from the French ASSESS cohort and idiopathic iTTP patients from the French TTP Registry. Demographic, clinical and biological data were retrospectively collected.
RESULTS: Thirty iTTP-SjD patients were included and compared with 65 pSjD and 45 idiopathic iTTP patients. The majority of iTTP-SjD patients (n=18) were diagnosed with SjD at the time of iTTP diagnosis. In comparison with the pSjD cohort, iTTP-SjD patients were diagnosed with SjD at a younger age (p=0.039) and showed a higher prevalence of anti-SjS-related antigen A antibody positivity and xerostomia (p=0.015, p=0.035, respectively). EULAR Sjogren's Syndrome Disease Activity Index showed similar activity levels between the two groups. iTTP-SjD patients were treated with plasma exchange (n=28), corticosteroids, rituximab (n=19) and caplacizumab (n=3). In comparison with the idiopathic iTTP cohort, mortality rates (log-rank tests, p=0.228), biological and clinical iTTP relapses (multivariate analysis, p=0.181) were comparable and short-term outcomes (survival at day 30, relapse) were favourable.
CONCLUSION: iTTP can be a rare complication in patients with SjD. Further studies involving larger cohorts and long-term follow-up are warranted to confirm these findings and to explore the efficacy of immunomodulators and caplacizumab in iTTP-SjD patients.
The invention is directed to an implantable device to enable delivery of drugs to the retina. The device minimizes stress to the retina by virtue of its softness and smooth shape that conform to the retina. Drugs are delivered by osmosis or by the device dissolving. It may be connected to an externally mounted pump and drug reservoir that control the amount of drug. It contains one or more holes that are positioned to deliver drugs to the desired location. Drugs may stimulate the retina to enable vision in blind patients. Drugs may be injected directly inside the eye by a trans-scleral pump and valve drug delivery device.
For patients in the control group,anaesthesia will be maintained with intravenous sodium chloride (NaCl; 0.9%) infusion.while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient. The assessment of the depth of anesthesia was based on clinical evaluation,placebo-controlled infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
PROBLEM TO BE SOLVED: To obtain an antioxidant capable of exhibiting effectiveness for prevention of the oxidation of lipid components of skin, oxidation damage to skin and skin aging by adding the antioxidant to a cosmetic, etc., comprising an extract of a specific plant known as a Japanese and Chinese medicine as an active ingredient. SOLUTION: This antioxidant comprises an extract of Leonurus sibiricus as an active ingredient. Leonurus sibiricus (flower, fruit, leaf, stem, skin, root, etc.) is extracted with a solvent such as a polar solvent, e.g. water or a lower alcohol or chloroform or dichloroethane to give an extracted solution, which is used as it is as the extract of Leonurus sibiricus or an essence obtained by concentrating the extracted solution or the residue obtained after removal of impurities from the essence is used. The amount of the extract of Leonurus sibiricus blended is 0.00001-5.0wt.%, preferably 0.00005-2.0wt.% calculated as a dried substance. Anti-oxidizing effects are exhibited by the blended amount. A cream, a lotion, a milky lotion, a shampoo, a rinse, etc., may be cited as the object to be mixed with the antioxidant.
The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
The present invention discloses a tumour targeting development composition for magnetic resonance imaging diagnosis and a preparation method thereof. The components of the composition comprise: an external water phase and a modified liposome body of phospholipids suspended in the external water phase, and the modified liposome body of phospholipids comprises a paramagnetic developer therein, polyethylene glycol covering the outer surface of the liposome body of phospholipids for leakage resistant modification or derivatives thereof and/or polypeptide numerators covering the outer surface of the liposome body of phospholipids for targeting modification. The coverage rate of the paramagnetic developer in the liposome is not lower than 60 percent so that the background noise during the magnetic resonance imaging is prominently reduced and the contrast quality of the image is improved. The liposome is good in physical chemistry stability and small in particle size. With the micropore degerming process, the liposome is suitable for the storage conditions of general developers, and is convenient in use. With the synergistic effect of the polypeptide targeting, not only early tumour can be found, but the effective observation time of the magnetic resonance imaging is prolonged to more than 2 hours.
Stage IV EGFR-mutant NSCLC patients who are currently receiving first line osimertinib treatment and have received at least 3 months, but no more than 6 months, of osimertinib with a best response of PR or SD. Patients may receive alisertib therapy until lack of clinical benefit or intolerable toxicity.
Because Dantrium Intravenous must be administered at a low concentration in a large volume of fluid, acute toxicity of Dantrium Intravenous could not be assessed in animals. In 14-day (subacute) studies, the intravenous formulation of Dantrium was relatively non-toxic to rats at doses of 10 mg/kg/day and 20 mg/kg/day. While 10 mg/kg/day in dogs for 14 days evoked little toxicity, 20 mg/kg/day for 14 days caused hepatic changes of questionable biologic significance.

Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria.

For acute overdosage, general supportive measures should be employed.

Intravenous fluids should be administered in fairly large quantities to avert the possibility of crystalluria. An adequate airway should be maintained and artificial resuscitation equipment should be at hand. Electrocardiographic monitoring should be instituted, and the patient carefully observed. The value of dialysis in Dantrium overdose is not known.
CAS is an alternative to CEA for treating carotid stenosis with a similar efficacy in preventing future stroke. High-intensity signal in the plaque on the TOF-MRA is associated to a high risk of cerebral embolism during stenting. The evidence of protection selection in such patients was limited. A single center, prospective, outcome- assessor-blinded, randomized controlled trial study (CASH-ES) is designed to compare the efficiency of two distal embolism protection devices (SpiderFX and Emboshield NAV6) during CAS procedure of patients with vulnerable plaque. Asymptomatic patients with internal carotid artery stenosis ≥ 70% (NASCET) and symptomatic patients with a stenosis ≥ 50% who is over 70 years old, diagnostic of vulnerable plaque on ultrasound or have a high-intensity signal in the relevant plaques on TOF-MRA will be included. Patients are randomized in two balanced groups (1:1) to receive CAS with either distal (Spider FX) or distal (Emboshield NAV6) protection. The primary endpoint is the incidence of new cerebral ipsilateral ischemic lesions on the DW-MRI within 7-days post operation. Secondary endpoints include the number, size, location of new cerebral ischemic lesions on the DW-MRI, the counts of MES during TCCD monitoring during procedure, procedural complications, stroke, myocardial infarction, and death within 7 days.
BACKGROUND: Transradial access (TRA) is now the default access site for PPCI, but technically is a more challenging approach mostly due to anatomic challenges connected to the RA.
AIMS: To assess the differences according to sex in radial artery (RA) access site characteristics during primary percutaneous coronary intervention (PPCI) for ST segment elevation myocardial infarction (STEMI).
MATERIAL AND METHODS: All 5092 consecutive STEMI patients from our center in the period from March 2011 until December 2017 were examined. The right proximal radial was the "intention-to-treat" access in all patients. Preprocedural RA angiography was performed in all patients. Clinical and procedure characteristics, type of radial anatomy variants, need to use another arterial access sites (the primary endpoint for this study), and procedure time were analyzed by sex. Using logistic regression, we selected predictors of radial crossover. Access site bleeding complications and vascular complications were also recorded.
RESULTS: The STEMI population in this period included 1326 females and 3766 male patients. Females were older (65 ± 11 years) than males (59 ± 11 years, p < 0.0001). Among standard risk factors, hypertension and diabetes mellitus were more common in women and smoking less common. RA anomalies were more frequent in the females (8.8% vs. 6.5%, p < 0.0001), with complex RA loop and tortuous RA twice as frequent in women. Failure of TRA access as the initially chosen site occurred in 4.6% (61) of females versus 2.5% (97) of male STEMI patients (p = 0.0003). The most common subsequent access site was right ulnar access in both groups (57 and 61% respectively). Access site bleeding complications were more common in women 4.4% versus 3.2%, mirrored in hematomas with EASY score III to V. Clinical RA spasm (RAS) was significantly more frequent in females (5.7% vs. 2.2%, p < 0.0001). Multiple regression analysis identified 5 independent predictors for TRA access crossover: previous TRA, anomalous RA, RAS, along with female sex and diabetes.
CONCLUSION: Female sex is a significant predictor of more complex TRA in STEMI. Understanding sex differences and predictors for TRA crossover will strengthen the use of different procedural modalities that can help in preserving a successful wrist access in female STEMI patients.
PROBLEM TO BE SOLVED: To obtain a product for bathing use capable of satisfying playful mind and giving amusing or pleasure feeling to everyone taking a bath by providing a plurality of chipped bath preparations and a plurality of the corresponding containers for the preparations. SOLUTION: This product for bathing use is obtained by providing (A) a plurality of chipped bath preparations 1a-1c and (B) a plurality of the corresponding containers 2a-2c for the preparations each consisting mainly of pref. a water- soluble base material (e.g. pullulan). The component B is desirably arranged so as to be in layers or in an engagedly manner. The shape of the component A may have a plant body shape, flower-like shape, petaloid shape or the like, and the component B may be in a polyhedral shape, spherical shape, columnar shape or the like. The components A and B may each contain any of perfumes, coloring agents, inorganic salts, organic acids, moisturizers, moisture absorbents, saccharides, higher fatty acids, oils, surfactants, foaming agents, physiologically active substances, enzymes, and crude drugs.
Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A). Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
Remote ischemic preconditioning (RIPC) was first described three decades ago as an intervention to protect vital organs from ischemic injury. RIPC occurs when a tissue is made transiently ischemic (5 minutes) for repeated bouts (5 times) prior to the longer ischemic insult. Recently it has been shown exercise performance and motor function are improved in young, healthy individuals when RIPC is performed on the arm or leg using a simple blood pressure cuff to occlude blood flow to the limb. The application of RIPC to individuals with reduced functional capacity, however, is largely unexplored. The study team was the first to apply RIPC to chronic stroke survivors with reduced physical function, and two weeks of RIPC increases walking speed, paretic muscle strength and fatigue resistance. Advanced age and cancer are both dramatic accelerators of frailty and frail patients have poor surgical outcomes. Therefore, the investigators propose to apply this non-invasive, simple intervention as a "prehabilitation" therapy to elderly patients with colon cancer during the perioperative period. The investigators will enroll 96 colon cancer patients aged 55-85 who are ≥17 days prior to scheduled curative resection of colon cancer. After study enrollment, all participants will perform the six-minute walk test as a measure of frailty. Participants will then be randomized to receive either RIPC on their upper, non-dominant arm daily for 14 days prior to surgery, or to receive standard of care (no intervention). After 14 days of either RIPC or no intervention, the 6-minute walk test will be re-assessed within 48 hours of surgery. The primary study outcome will be the difference in six-minute walk distance (in meters) between patients in the RIPC group vs. those in the standard of care group following the two-week pre-operative intervention period (Aim 1). The investigators hypothesize that patients in the RIPC group will walk further during the six-minute walk test than those in the standard of care group due to the well-defined effects of RIPC to improve athletic performance, cardiovascular function, and strength in healthy individuals. A secondary study outcome will be the difference in six-minute walk test distance between the RIPC and standard of care group 4-weeks postoperatively (Aim 2). The investigators hypothesize that patients in the RIPC group will have more rapid recovery from surgery, which would be evidenced by increased walking endurance post-operatively. Another secondary study outcome will be the amount of intraoperative blood pressure variability (time systolic pressure is above or below 135 mmHg or 95 mmHg, respectively) between the RIPC and control groups (Aim 3). The investigators hypothesize that RIPC will reduce intraoperative blood pressure variability due to the well described effects of RIPC to improve systemic vascular function. Future larger studies will examine the effects of RIPC prehabilitation on surgical outcomes such as length of hospital stay and all-cause mortality in frail, elderly patients with colon cancer as well as other patient cohorts with reduced functional capacity.
FIELD: medicine, pharmacology. SUBSTANCE: antihypoxic agent has, mas. p. p.: 3,5-diamino-1,2,4-thiadiazole, 1; succinic acid, 0.3-0.6; polyglucin, 0.7-1.3, and sodium hydroxide, up to pH = 5.5-8.5. Method of preparing involves the following stages: dissolving 3.5-diamino-1,2,4-thiadiazole together with polyglucin in water at 50-75 C, addition of succinic acid to solution and titration of the obtained mixture with sodium hydroxide solution to pH = 5.5-8.5. Then solution is kept at temperature of its preparing following by cooling, sterile filtration and sublimating drying. Sterile lyophilized powder is obtained. New antihypoxic agent is water-soluble, stable at storage, has neutral reaction, can be sterilized, has high antihypoxic effect and decreased local irritating action at parenteral administration. EFFECT: improved quality, enhanced effectiveness of agent. 2 cl, 4 tbl
All participants will run the task consisting in 2 squares moving towards each other. On each trial they will answer whether the squares touch or do not touch. All participants are tested with all experimental conditions. The rate of 'touch' responses will be compared when there is a trajectory perturbation without rebound vs. a trajectory with perturbation with rebound vs. a trajectory without perturbation and without rebound vs. a trajectory without perturbation and with rebound.
The invention provides an information processing system capable of realizing more accurate transmission or sharing of information related to medical procedures. According to one aspect of the present invention, an information processing system is provided. The information processing system includes a control unit. The control unit is configured to execute the following steps. In the reading step, reference information related to a reference procedure that is a medical procedure that the user wishes to reference is read. The reference information includes a three-dimensional position of the tracking point of the reference technique. In the first accepting step, a photographed image of the outside world visually recognized by the user is accepted. In the generating step, display information for presenting augmented reality related to the reference technique to the user is generated based on the three-dimensional position at the tracking position and the captured image. In augmented reality, the shape of a medical instrument used in a reference procedure or a hand that operates the medical instrument is reproduced three-dimensionally.
This group will start with a Simulation and debrief followed by a didactic lecture afterwards. They will then complete a simulation 2 months later.
Tizanidine, an α2-adrenergic receptor agonist commonly prescribed as a muscle relaxant, has been associated with limited cases of acute intoxication or withdrawal. Here, we present a case of tizanidine withdrawal in a woman in her 40s who presented with an unusual combination of systemic and neurological symptoms. These included hallucinations, decorticate posture, limb and eyelid tremors, along with hypertension, tachycardia and tachypnoea. The diagnosis of tizanidine withdrawal was established by a comprehensive assessment of the patient's medical history and the systematic exclusion of other potential diseases. Our approach to managing the withdrawal symptoms was to initiate symptomatic treatment with a combination of a beta-blocker and a calcium channel blocker. Remarkably, this intervention successfully resolved both vital signs and neurological manifestations by the following day. In conclusion, tizanidine withdrawal is associated with a distinct and diagnostically significant neurological syndrome characterised by hallucinations, decorticate posture, tremors and hypersympathetic vital signs.
The invention relates to dietetic foods in the context of weight control or weight reduction, comprising at least one n3 fatty acid (omega-3) in combination with dietary fibers. Advantageously, the foods further comprise a balanced ratio of carbohydrates, protein and fat. Preferably, the inventive foods comprise a balanced ratio of fatty acids, in particular relating to the ratio n3 to n6 fatty acids (approximately 1:1 to 1:10). The inventive food combinations serve the purpose of a sufficient supply of essential fatty acids, in particular long-chain omega-3 fatty acids, in particular docosahexaenoic acid (DHA), in the context of a targeted weight reduction. The inventive food combinations are of particular advantage in the case of restricted fat supply, e.g. in the context of a reduced-fat diet with the purpose of weight reduction or weight control. In addition, the invention relates to a method for producing such dietetic foods, and also to their use.
A droplet formation for fuels is disclosed. The droplet formation for fuels includes an amphiphile. The droplet formation for fuels further includes at least one of an extensional viscosity modifier and a viscosity modifier. The droplet formation for fuels further includes a hydrophilic portion. The droplet formation for fuels further includes a hydrophobic portion. The droplet, including the hydrophilic portion and the hydrophobic portion, includes characteristics selected for beneficial combustion properties. The selected characteristics include flash point, autoignition temperature, density, viscosity, miscibility, size, combustion temperature, organic properties, inorganic properties, zwitterionic properties, micelle properties, and particulate properties.
PURPOSE:To obtain in high recovery an IgG pharmaceutical for intravenous injection with low anticomplementary activity, through such processes that flocculates are removed from an aqueous IgG solution followed by filtration in the presence of a surface-active stabilizer through a polyolefin porous membrane to effect prevention of IgG flocculation. CONSTITUTION:Flocculates are removed from an aqueous solution of immunoglobulin G fractionated from human plasma to such an extent as not to be detectable by gel permeation analysis. The resulting solution is then filtered, in the presence of a surface-active stabilizer such as serum albumin, corn fraction V, polyvinylpyrrolidone or polyethylene glycol, through a porous polyolefin membrane 0.015-0.17 (esp. 0.02-0.06)mum in the pore size determined by the uniform particle filtration technique. For removing the flocculates, an adsorption technique using tricalcium phosphate is preferable. The IgG concentration in the IgG stock solution in performing the membrane filtration is pref. 1-10wt.%, and 0.1-1 pt.wt. of the stabilizer is used based on 1 pt.wt. of IgG.
The selected womens were associated with obesity risk factors about obesity (overweight) or obese and between 18-49 years old) and randomly assigned to the experimental group. Obesity training consisting of a total of five sessions structured according to Theory of Planned Behavior was scheduled for the intervention group. Each session lasted for approximately 30 minutes.
Egg diet, contains 2 eggs per day and limits saturated fat to 6% of energy intake. Cholesterol intake is 600mg/day. Protein and carbohydrate levels will be maintained at 20% and 40% of energy intake, respectively. This diet will be followed for 5 weeks.